Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Synovial, skin gene expression differences may explain PsA treatment responses

Publish date:: December 11, 2020

Key clinical point: Different gene expression in synovial tissue, compared with skin, may explain differing treatment responses for skin and joints in psoriatic arthritis treated with anti-TNF agents and the anti–IL-23/IL-12 inhibitor ustekinumab.

Major finding: Some patients with psoriatic arthritis have lower levels of gene expression for key drug targets in their synovial tissues.

Study details: Observational, open-label study in 27 patients with active psoriatic arthritis.

Disclosures: The study was supported by the Queen Mary University of London and the Fondazione Ceschina, and in part by grants from Versus Arthritis. No conflicts of interest were declared.

Citation:

Nerviani A et al. Ann Rheum Dis. 2020. Nov 26. doi: 10.1136/annrheumdis-2020-218186.

This Week's Must Reads

Synovial, skin gene expression differences may explain PsA treatment responses,

Guselkumab improvements for psoriatic arthritis persist through 1 year,

Biologics may delay psoriatic arthritis, study finds,

PASDAS beats DAS28 in measuring psoriatic arthritis treat-to-target success,

Entheseal lesions, bone density linked with incident PsA in psoriasis patients,

Must Reads in Psoriasis

Synovial, skin gene expression differences may explain PsA treatment responses,

Biologics may delay psoriatic arthritis, study finds,

Biologics yield low rates of skin clearance in real-world psoriasis study,

Financial incentives affect the adoption of biosimilars,

Genome study examines heritability of psoriatic disease subtypes,